Live chat
Biogen

Scientist II, Small Molecule Target Biochemical Enzymologist

Biogen - Cambridge, MA

We are seeking an enthusiastic, organized and creative biochemistry scientist for our research bioassay group in Cambridge, MA. The ideal candidate will be a motivated scientist who can lead from the bench and enjoys additional collaborative opportunities. Must be an enzymology expert who can support small molecule research teams by providing biochemical routine assay support and mechanism of action studies to enable SAR studies for our early and late discovery teams.

Duties & Responsibilities:

•\tDesign and development of novel biochemical assays using a wide variety of detection methods (spectroscopic, radiometric, colorimetric, fluorescence, etc.) and expertise in data analysis.

•\tAbility to develop immunoprecipitation assays on relevant biochemical complexes.

•\tManage the entire system of outsourcing routine screening run by external CRO including: ordering compounds from compound manager, tracking compound shipments, validating analysis of data and interpretation, enable uploading of data into LIMS systems.

•\tWork closely with project teams and high throughput screening group to support miniaturization and adaption of biochemical assays for high throughput screening.

•\tServe as a project team coordinator to ensure efficient transfer of information and reagents throughout the support groups for Medchem SAR design.

•\tSupervise one associate scientist delivering biochemical assay support to project teams through weekly SAR screens.

•\tPerform mechanism of action studies to understand competition, off-rates, on-rates and other.

Requisition Number

32927BR

Employment Category

Full-Time Regular

External Posting Title

Scientist II, Small Molecule Target Biochemical Enzymologist

Job Category

Research & Development

Qualifications

Broad drug discovery experience with diverse classes of enzyme targets (e.g. kinases, GPCRs, ion channels, E3-ligases) is strongly preferred. The candidate should be experienced in managing research efforts by others and have excellent written and verbal communication skills. Familiarity with all techniques and hardware/software relevant to high throughput screening is a plus. Must be a team player with strong leadership and team-building skills.

Education

Ph.D.and post-doctoral experience in Biochemistry or related discipline and 3-5 years in industry.

Experience Level

Mid-Senior Level

Summary

We are seeking an enthusiastic, organized and creative biochemistry scientist for our research bioassay group in Cambridge, MA. The ideal candidate will be a motivated scientist who can lead from the bench and enjoys additional collaborative opportunities. Must be an enzymology expert who can support small molecule research teams by providing biochemical routine assay support and mechanism of action studies to enable SAR studies for our early and late discovery teams.

Action

9 days 8 hours ago

Biogen

apply

Scientist II, Small Molecule Target Biochemical Enzymologist Biogen - Cambridge, MA, United States

   

Location: Cambridge, MA

Company Profile:
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company’s products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company’s Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.